Grace Therapeutics, Inc. logo

Grace Therapeutics, Inc.(GRCE)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.81
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for GRCE

11/13/2026: GRCE (1-star) is currently NOT-A-BUY. Pass it for now.

Grace Therapeutics is a micro-cap, clinical-stage biopharmaceutical company specializing in proprietary drug formulations for rare and orphan diseases. The company's primary strength lies in its late-stage pipeline candidate, GTx-104, designed to treat aneurysmal subarachnoid hemorrhage. Its main growth opportunity centers on clearing regulatory hurdles and achieving commercialization. However, the company faces substantial execution risks, continuous cash burn, and dependence on external financing. The stock suits high-risk growth investors willing to tolerate volatility while monitoring regulatory updates and cash runway milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth optionality tied to clinical milestones, tempered by early-stage pipeline risks.
Momentum investorStrong fit while signal remains positiveShort-term momentum can spike around major clinical data readouts and regulatory updates, conditional on positive price trends.
Value investorWeak fitThe absence of commercial earnings and ongoing cash burn make traditional value metrics inapplicable.
Dividend investorWeak fitThe company is pre-revenue and does not pay dividends, retaining all cash for clinical development.
Low-risk investorWeak fitHigh share price volatility and binary clinical-regulatory outcomes present substantial risk for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical-stage biotech stocks frequently experience sharp price swings based on news flow and market sentiment.
Valuation riskHighValuation relies heavily on speculative future cash flows from unapproved drug candidates.
Competition risk (specialty pharma and orphan drug developers)Medium / highThe company faces intense competition from well-funded peers targeting similar rare disease indications.
Business qualityMediumThe underlying asset quality is defined by promising drug delivery technology, though commercial proof remains pending.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess depends entirely on successfully managing clinical trials, manufacturing standards, and regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 38.08M USD
Price to earnings Ratio -
1Y Target Price 5.85
Price to earnings Ratio -
1Y Target Price 5.85
Volume (30-day avg) 104.1K shares
Beta 0.41
52 Weeks Range 1.67 - 5.18
Updated Date 11/15/2026
52 Weeks Range 1.67 - 5.18
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.16

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -39.25%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
GRCE receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
GRCE has moderate overall fundamentals (3 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2026 versus FY2025, strong earnings growth (+42.8%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
GRCE's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is GRCE's strongest growth driver at +42.8% FY2026 versus FY2025 (strong, 5 stars). By comparison, free-cash-flow growth (+40.5%, strong) is also strong, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 33.0% and approximately 63.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 18.68% supports management-shareholder alignment.

Top 5 Institutional Investors

HPM Partners LLC 4.04%
Eversept Partners, LP 3.67%
Bank of America Corp 2.35%
Vanguard Capital Management, LLC 1.96%
Citadel Advisors Llc 1.66%

Unit Economics (Per $1K Revenue)

★★★★★
GRCE generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 17.91%

Quantitative Style Profile

★★★★★
GRCE has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Operations / Product SalesCurrently pre-revenue, future monetization is expected to stem from commercializing specialized pharmaceutical products for rare diseases.The company does not currently sell commercial drugs for profit; investors are betting on future regulatory approvals.
Licensing and PartnershipsPotential future milestone payments, upfront fees, and royalties derived from co-development or commercialization agreements.Strategic partnerships could provide non-dilutive funding and validation for pipeline assets.

Valuation

Trailing PE -
Forward PE 2.17
Enterprise Value 16.76M
Price to Sales(TTM) 197.75
Enterprise Value 16.76M
Price to Sales(TTM) 197.75
Enterprise Value to Revenue 5.5
Enterprise Value to EBITDA 19.61
Shares Outstanding 21.04M
Shares Floating 13.27M
Shares Outstanding 21.04M
Shares Floating 13.27M
Percent Insiders 18.68
Percent Institutions 33.05

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.